Ascimib 40 mg Tablet

Description

Ascimib Asciminib 40 mg Tablet contains Asciminib, a targeted therapy used to treat Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML). It helps control cancer cell growth in patients resistant or intolerant to previous treatments.

Benefits

• Targets CML cells with high precision

• Effective in patients resistant to multiple TKIs

• Helps achieve and maintain molecular remission

• Oral therapy for convenient long-term treatment

• Lower risk of some TKI-related side effects

Indications and Usage

Ascimib Asciminib 40 mg Tablet is indicated for:

• Ph+ Chronic Myeloid Leukemia (CML) — Chronic Phase

• Patients previously treated with at least one TKI

• Patients resistant or intolerant to prior CML therapies

Therapy must be prescribed and managed by a hematologist/oncologist.

How it Works

Asciminib uniquely targets the ABL myristoyl pocket, blocking BCR-ABL1 signaling responsible for leukemia cell growth. This disrupts cancer cell survival and slows disease progression while sparing healthy cells.

Dosage & Administration

• Typical dose: 40 mg once or twice daily, or as prescribed

• Take with or without food, at the same time daily

• Swallow tablets whole—do not crush or chew

• Do not skip or double doses

• Regular blood tests and clinical monitoring required

Use only under oncologist supervision.

Side Effects

Common side effects:

• Fatigue

• Nausea

• Headache

• Joint or muscle pain

• Rash

• Low blood counts

Serious side effects (seek urgent care):

• High blood pressure

• Pancreatitis

• Severe myelosuppression

• Heart-related symptoms

• Severe allergic reactions

Warning and Precaution

• Not recommended during pregnancy or breastfeeding

• Use cautiously in patients with hypertension or pancreatic disease

• Monitor blood counts, liver enzymes, and blood pressure regularly

• Inform doctor about all current medications to avoid interactions

• Report abdominal pain, unusual fatigue, bleeding, or chest pain immediately